Radiation boost may help control advanced pancreatic cancer
NCT ID NCT07600268
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests whether adding a precise, high-dose form of radiation (SBRT) to standard maintenance chemotherapy can help people with advanced pancreatic cancer live longer. The study enrolls 24 adults whose cancer has not grown after at least four months of initial chemo. Participants are randomly assigned to receive either maintenance chemo alone or maintenance chemo plus SBRT. The main goal is to see if the combination improves one-year survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Stereotactic body radiotherapy (SBRT) plus maintenance chemotherapy
- What this could lead to
- If successful, this could offer a new way to extend survival for people with advanced pancreatic cancer by adding targeted radiation to standard maintenance therapy.
- What could go wrong
- This is a small, early-phase trial with only 24 participants, so results may not apply to everyone. The added radiation also carries risks like fatigue or digestive issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shandong Cancer Hospital and Institute
RECRUITINGJinan, Shandong, 250021, China
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI trained on thousands of pancreatic cancer cases could revolutionize diagnosis
- New device aims to make pancreatic and bile duct procedures safer
- New Antibody-Drug combo takes on Hard-to-Treat pancreatic cancer
- New drug combo aims to shrink Hard-to-Treat pancreatic and ovarian tumors
- Drug cocktail aims to stall pancreatic cancer in patients who have run out of options
- Experimental vaccine combo takes on tough pancreatic cancer